Most significantly, Yuan’s team established that Abraxane decreased breast cancer stem cell frequency by 3- to ninefold through increased intracellular drug uptake (3- to 15-fold) in both ALDH + cancer stem cells and differentiated ALDH- cells, whereas conventional Taxol paradoxically increased cancer stem cell populations. This evidence concerns the gene LDHA and breast carcinoma.